Abstract
Biogen is paying Sangamo Therapeutics $350 million up front to develop gene therapies for neurological diseases. The deal focuses on Sangamo’s zinc finger protein transcription factors (ZFP-TFs), which dial the expression of genes up or down. The two most advanced programs in the collaboration use ZFP-TFs to decrease levels of tau proteins and α-synuclein proteins, implicated in Alzheimer’s and Parkinson’s disease, respectively. Biogen has exclusive rights to develop Sangamo’s ZFP-TFs for up to 10 additional targets.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
